Who are Novel hormonal therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antiandrogen Therapy, Add-back therapy, ADT (Standard of Care), tamoxifen + exemestane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/novel-hormonal-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Novel hormonal therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel hormonal therapy (novel-hormonal-therapy) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: hormonal therapy. Area: Oncology.

marketed hormonal therapy hormone receptors, EGFR Oncology Live · refreshed every 30 min

Target snapshot

Novel hormonal therapy (novel-hormonal-therapy) — Pfizer.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Novel hormonal therapy TARGET	novel-hormonal-therapy	Pfizer	marketed	hormonal therapy	hormone receptors, EGFR
Antiandrogen Therapy	Antiandrogen Therapy	M.D. Anderson Cancer Center	phase 3	Androgen receptor antagonist / Hormonal therapy	Androgen receptor (AR)
Add-back therapy	Add-back therapy	Bio Genuine (Shanghai) Biotech Co., Ltd.	phase 3	Hormone replacement therapy / Adjunctive hormonal therapy
ADT (Standard of Care)	ADT (Standard of Care)	Aragon Pharmaceuticals, Inc.	phase 3	Hormonal therapy / Androgen deprivation	Androgen receptor / GnRH receptor (depending on specific ADT agent)
tamoxifen + exemestane	tamoxifen + exemestane	Pfizer	phase 3	Hormonal therapy combination (selective estrogen receptor modulator + aromatase inhibitor)	Estrogen receptor alpha (ESR1) and aromatase (CYP19A1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (hormonal therapy class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Novel hormonal therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/novel-hormonal-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab